Brandes Investment Partners LP Has $141.54 Million Stock Holdings in Icon Plc $ICLR

Brandes Investment Partners LP boosted its position in shares of Icon Plc (NASDAQ:ICLR) by 2.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 776,732 shares of the medical research company’s stock after buying an additional 21,072 shares during the quarter. Brandes Investment Partners LP’s holdings in Icon were worth $141,538,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of ICLR. Harris Associates L P acquired a new position in Icon during the 2nd quarter worth $238,256,000. Capital World Investors lifted its holdings in Icon by 555.2% during the 4th quarter. Capital World Investors now owns 1,496,479 shares of the medical research company’s stock worth $272,688,000 after buying an additional 1,268,095 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Icon by 26.6% in the 3rd quarter. Wellington Management Group LLP now owns 4,637,137 shares of the medical research company’s stock valued at $811,499,000 after purchasing an additional 975,268 shares during the period. Lyrical Asset Management LP acquired a new position in shares of Icon in the 4th quarter valued at $176,382,000. Finally, Norges Bank acquired a new position in shares of Icon in the 4th quarter valued at $160,073,000. Institutional investors and hedge funds own 95.61% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Robert W. Baird set a $119.00 price target on Icon in a research note on Friday, February 13th. Truist Financial increased their price target on Icon from $139.00 to $159.00 and gave the company a “hold” rating in a research note on Friday, May 29th. Leerink Partners set a $145.00 price target on Icon in a research note on Thursday, May 28th. Zacks Research downgraded Icon from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 25th. Finally, Citigroup increased their price target on Icon from $120.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, May 29th. Eight investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Icon presently has a consensus rating of “Hold” and an average price target of $156.44.

Icon Price Performance

ICLR opened at $151.82 on Wednesday. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.31. Icon Plc has a 12 month low of $66.57 and a 12 month high of $211.00. The company has a fifty day simple moving average of $119.49 and a 200 day simple moving average of $140.63. The stock has a market cap of $11.62 billion, a P/E ratio of 24.65, a P/E/G ratio of 12.03 and a beta of 1.26.

Icon (NASDAQ:ICLR) last released its quarterly earnings data on Wednesday, June 10th. The medical research company reported $2.52 EPS for the quarter, beating analysts’ consensus estimates of $2.47 by $0.05. Icon had a net margin of 5.98% and a return on equity of 9.50%. The business had revenue of $2.11 billion during the quarter, compared to analysts’ expectations of $1.99 billion. During the same quarter in the prior year, the company earned $3.43 EPS. The firm’s quarterly revenue was up 2.5% on a year-over-year basis. On average, research analysts expect that Icon Plc will post 9.74 EPS for the current year.

Icon Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.